Connect with us

Australia

Opyl partners with hummun to provide end-to-end digital solutions for pharma and medtech industry

Opyl Ltd (ASX:OPL) has partnered with hummun in a strategic move designed to drive client acquisition, uptake of Opyls social media services within major pharma and medtech, and ultimately grow revenue.

The initial two-year collaboration agreement with UK-based hummun is aimed at efficiently leveraging skills, infrastructure, digital and data technology solutions within both companies to drive mutual growth and value.

This will see Opyls AI-powered market insights and social media expertise added to hummuns suite of digital sales and marketing solutions.

hummun is a sales, marketing and medical communications company that develops and employs smart digital technologies with clients, many of whom are global leaders in life sciences.

The collaboration allows the two companies to provide an extended, sophisticated end-to-end sales and marketing offering across traditional and digital platforms.

“Terrific fit for Opyl”[hhmc]
Opyl chief executive officer Michelle Gallaher said: “We are..

Opyl Ltd (ASX:OPL) has partnered with hummun in a strategic move designed to drive client acquisition, uptake of Opyls social media services within major pharma and medtech, and ultimately grow revenue.

The initial two-year collaboration agreement with UK-based hummun is aimed at efficiently leveraging skills, infrastructure, digital and data technology solutions within both companies to drive mutual growth and value.

This will see Opyls AI-powered market insights and social media expertise added to hummuns suite of digital sales and marketing solutions.

hummun is a sales, marketing and medical communications company that develops and employs smart digital technologies with clients, many of whom are global leaders in life sciences.

The collaboration allows the two companies to provide an extended, sophisticated end-to-end sales and marketing offering across traditional and digital platforms.

“Terrific fit for Opyl”


Opyl chief executive officer Michelle Gallaher said: “We are very excited to collaborate with Paul Hartigan and the hummun global team – they are a terrific fit for Opyl in terms of the quality, novelty and performance of the digital solutions they create, their market leadership position and values.

“hummun has an impressive track record in the global market and an enviable client base and their unique digital Early Access Gateway complements our clinical trial recruitment offering and AI-driven market insights capabilities.

“We are looking forward to getting in front of clients together in Australia in the coming days.”

Opyl is in a growth phase as it looks to globally roll out and extend its expertise abilities in evidence-based digital marketing and sales strategy, content creation and deep market insight.

The partnership with hummun helps Opyl to accelerate its global reach and allows humman to leverage Opyls complimentary services and technologies with their clients.

“Deep experience with social networks”


hummun managing director Paul Hartigan said: “We are delighted to partner with Opyl and look forward to exploring new frontiers in digital health and data solutions.

“Opyls deep experience with social networks and new AI-assisted offering in health-related social media engagement and insights is of particular value to the hummun team, complementing our unique platforms and development capabilities perfectly.”

Agreement benefits


The benefits to Opyl include:

  • A wider end-to-end client offering combining Opyl and hummuns technologies and service capabilities;
  • Significant expansion of business development and sales support for Opyl with minimal infrastructRead More – Source
Continue Reading

Australia

THC Global targets product range expansion and entry into Asia Pacific, Latin America markets

THC Global Group Ltd (ASX:THC) plans to expand its product range and move into new territories in 2021 and beyond as it boosts production at its Southport facility to meet demand from New Zealand and Canadian markets.

The company is targeting to enter the Asia Pacific market in 2021+ with identified potential markets in Thailand, Malaysia, China, South Korea and Japan.

It also sees Latin American and other international opportunities to open with the pharma over-the-counter (OTC) cannabis scale-up.

THC Global operates across the cannabis supply chain, from cultivation, extraction, and direct patient and prescriber support services.

Milestones achieved[hhmc]
THC Global chairman Steven Xu said: “Over the past few months we have achieved several key milestones including launching our Canndeo medicines in Australia, supplying our first prescriptions and signing new production agreements.

“We look forward to building on top of these successes in the coming months and toward supporting ..

THC Global Group Ltd (ASX:THC) plans to expand its product range and move into new territories in 2021 and beyond as it boosts production at its Southport facility to meet demand from New Zealand and Canadian markets.

The company is targeting to enter the Asia Pacific market in 2021+ with identified potential markets in Thailand, Malaysia, China, South Korea and Japan.

It also sees Latin American and other international opportunities to open with the pharma over-the-counter (OTC) cannabis scale-up.

THC Global operates across the cannabis supply chain, from cultivation, extraction, and direct patient and prescriber support services.

Milestones achieved


THC Global chairman Steven Xu said: “Over the past few months we have achieved several key milestones including launching our Canndeo medicines in Australia, supplying our first prescriptions and signing new production agreements.

“We look forward to building on top of these successes in the coming months and toward supporting our target of 6,000 patients using a THC Global produced medicinal cannabis medicine by the end of 2020.”

Export markets


The company has secured agreements to export into Europe, New Zealand and Canada with effect from the third quarter of 2020, with the initial products focusing on CBD medicines range.

Its cannabis medicines are now competitively positioned for direct supply into Canada after receiving Health Canada licensing for Class I, II, III devices and Natural Health Products. Canada has an established market of more than 350,000 registered patients.

It has also inked deals with leading pharmaceutical distributors for New Zealand, as well as to provide prescriber support on cbdinfo.co.nz.

The first order from Medleaf Therapeutics in New Zealand has been received, with an initial supply of 2,250 bottles at $260,000, to be delivered on October 1, 2020.

This order is expected to support up to 800 patients in New Zealand on an ongoing basis.

THC Global is competitively positioned in the New Zealand market due to the requirement from October 2020 for the supply of all future medicines into the country, including future locally sourced medicines, to meet stringent registration requirements.

These include the provision of a six-month expiry date on medicines, which will be a significant time barrier on new market entrants based in New Zealand.

The European supply agreement with Germanys ACA Muller will see its products moving into more than 1,200 pharmacies across the European Union, with the first purchased supply into Europe expected in the fourth quarter this year.

THC Global is completing verification of Good Agricultural and Collecting Practice (GACP) supply for its external suppliers, which is a mandatory requirement for export into Europe.

The companys manufacturing facility is Good Manufacturing Practices (GMP) licensed by the Therapeutic Goods Administration in Australia and has reciprocal recognition across Europe in meeting EU-GMP requirements.

Domestic boost with rescheduling of CBD medicines


The company is also preparing for the rescheduling of CBD medicines in Australia, which is expected in the first quarter of 2021 and is readying products for the required specific Schedule 3 registration throughout 2020.

The Pharma Over-The-Counter (OTC) CBD medicines market will open supply to Australians via pharmacies without the need for a prescription.

THC believes it is the best placed to dominate this market with a global supply chain supplemented with large-scale, low-cost cultivation options and Australias largest capacity dedicated cannabis medicine manufacturing facility.

The value of the future Pharma OTC CBD medicines market has been projected to potentially exceed $200 million per year.

Spike in patient enquiries at Tetra Health


In June, Tetra Health, which THC Global acquired this year, received a 30% increase in patient inquiries and this trend is expected to continue.

In line with this, THC Global is expanding Tetra Healths clinical staff to ensure it can manage a continued increase in patients whilst ensuring a high level of patient support and care.

Tetra Health is a product-agnostic clinic, focused on medicinal cannabis prescribing, ongoing patient care and collecting real-world evidence on medicinal cannabis medicines.

It offers patients and prescribers a broad range of medicinal cannabis medicines, including THC Globals Canndeo medicines and medicines produced by THC Global uRead More – Source

Continue Reading

Australia

Peninsula Energy confirms strong director support for $40.3 million entitlement offer

Peninsula Energy Ltd (ASX:PEN) directors have acquired shares in the company via their participation in the recently completed $40.3 million entitlement offer.

Managing Director Wayne Heili acquired 1,290,476 shares, finance director/CFO David Coyne acquired 280,000 shares, non-executive chairman John Harrison added 37,800 shares and non-executive director Mark Wheatley bought 232,281 shares.

The newly acquired shares of Heili and Coyne also includes the vesting of previously approved Restricted Share Units and unlisted options to them.

Uranium production re-start strategy[hhmc]
The entitlement offer has allowed Peninsula to repay its existing term debt in full (principal amount of US$16.821 million (~$24.7 million) leaving the company cashed-up andRead More – Source

[contf]
[contfnew]

Proactiveinvestors
[contfnewc]
[contfnewc]

Peninsula Energy Ltd (ASX:PEN) directors have acquired shares in the company via their participation in the recently completed $40.3 million entitlement offer.

Managing Director Wayne Heili acquired 1,290,476 shares, finance director/CFO David Coyne acquired 280,000 shares, non-executive chairman John Harrison added 37,800 shares and non-executive director Mark Wheatley bought 232,281 shares.

The newly acquired shares of Heili and Coyne also includes the vesting of previously approved Restricted Share Units and unlisted options to them.

Uranium production re-start strategy


The entitlement offer has allowed Peninsula to repay its existing term debt in full (principal amount of US$16.821 million (~$24.7 million) leaving the company cashed-up andRead More – Source

Continue Reading

Australia

Infinity Lithium releases 3D video showcasing sustainable San José Lithium Project

Infinity Lithium Ltd (ASX:INF) has released a 3D video showing reproductions of what the sustainable San Jose Valdeflórez Lithium Project in Cáceres, Spain, will look like.

The video, which lasts for about two minutes, showcases how the project is designed to guarantee the protection of the citys ecosystem with the responsible use of water and health protection initiatives.

This digital recreation shows details of the mining area, the industrial plant and the tailings as well as the continuous rehabilitation of the site.

[embedded content]

Europe's second-largest lithium deposit[hhmc]
San José Valdeflórez, which is the second-largest lithium deposit in the European Union, is set to put Cáceres on the map of the electric vehicle (EV) sector.

INF is working to develop a sustainable project that offers opportunities for the strategic development of a fully integrated supply chain for EVs in Europe

The video states Cáceres has the opportunity to set an example globally with a te..

Infinity Lithium Ltd (ASX:INF) has released a 3D video showing reproductions of what the sustainable San Jose Valdeflórez Lithium Project in Cáceres, Spain, will look like.

The video, which lasts for about two minutes, showcases how the project is designed to guarantee the protection of the citys ecosystem with the responsible use of water and health protection initiatives.

This digital recreation shows details of the mining area, the industrial plant and the tailings as well as the continuous rehabilitation of the site.

Europe's second-largest lithium deposit


San José Valdeflórez, which is the second-largest lithium deposit in the European Union, is set to put Cáceres on the map of the electric vehicle (EV) sector.

INF is working to develop a sustainable project that offers opportunities for the strategic development of a fully integrated supply chain for EVs in Europe

The video states Cáceres has the opportunity to set an example globally with a technology that is already changing the world – electric mobility.

Lithium supply strategy


Infinity recently strengthened its European lithium supply strategy by executing binding agreementRead More – Source

Continue Reading

Trending